Axonyx Phenserine May Be First Alzheimer's Drug Targeting Beta-Amyloid
Axonyx' phenserine could be the first Alzheimer's disease agent targeting beta-amyloid plaques filed at FDA as companies look to move beyond the symptom relief offered by current therapies
You may also be interested in...
Novartis' and Cephalon's disease-modifying Parkinson's disease agents are approaching the final stages of development, with at least one pivotal trial slated to begin in 2004
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011